Recordati S.p.A. / EUSA Pharma (UK) Ltd.

Rare/niche oncology (high-risk neuroblastoma, Castleman disease, advanced RCC, oral mucositis)

800 US cases/yr · $5.0B Combined global rare-oncology niche market for EUSA portfolio (2024) · 845 Total Recordati-EUSA acquisition value (USD MM, ~EUR 750M EV)

Disease Overview

EUSA Pharma's portfolio addresses four distinct rare or specialty oncology populations. High-risk neuroblastoma is the most common extracranial solid tumor in children, with approximately 800 new US cases annually (NCI/SEER) and roughly half presenting as high-risk disease with five-year survival historically below 50%. Idiopathic multicentric Castleman disease (iMCD) is an ultra-rare lymphoproliferative disorder affecting approximately 5,000 patients in the US, characterized by IL-6 overproduction. Advanced renal cell carcinoma accounts for approximately 81,800 new US cases annually (SEER 2024) with metastatic disease driving demand for sequenced targeted therapies. Severe oral mucositis affects roughly 40-80% of patients receiving cytotoxic chemotherapy or head/neck radiation, with peak severity producing dysphagia, infection risk and dose interruptions. The combined rare-cancer market for these niches is approximately $4-5B globally, with high price-per-patient economics offsetting low volume. EUSA's commercial footprint spans Europe (where Qarziba is the standard of care for high-risk neuroblastoma) and selected ex-US markets, fitting Recordati's rare-disease consolidator playbook.

Competitive Landscape

Each of the four EUSA assets sits in a different competitive niche. High-risk neuroblastoma anti-GD2 mAbs: Qarziba (dinutuximab beta, EUSA, EU standard of care post-induction maintenance) and Unituxin (dinutuximab, United Therapeutics, US standard of care, ~$200M sales). Anti-IL-6 in iMCD: Sylvant (siltuximab, EUSA, the only FDA-approved iMCD therapy) faces no direct competitor but operates in a tight class with Actemra (tocilizumab, Roche IL-6R mAb, off-label for iMCD outside the US/EU label). Advanced RCC TKIs: Fotivda (tivozanib, EUSA EU rights / Aveo US rights) competes against Cabometyx (cabozantinib, Exelixis), Inlyta (axitinib, Pfizer), Lenvima (lenvatinib, Eisai/Merck) and the Sutent (sunitinib) and Votrient (pazopanib) generics, increasingly in IO-TKI combinations with Keytruda (pembrolizumab) and Opdivo (nivolumab). Oral mucositis: Caphosol (calcium phosphate rinse) competes with MuGard (Plus Therapeutics) and Episil (Cipla), all functioning as supportive-care devices rather than systemic therapies. Recordati gains a coherent specialty-oncology cluster that complements its existing rare-disease franchise (Cosmegen/Cystadrops/Cushing portfolio) and adds Europe-skewed cash-generating assets at attractive multiples relative to public oncology comparables.